Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Andexanet Alfa

Mirembe Reed, Preeti Patel, Diala Nicolas  1
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Book

Andexanet Alfa

Mirembe Reed et al.

Excerpt

This activity offers clinicians an in-depth review of andexanet alfa, the first FDA-approved recombinant factor Xa protein designed to rapidly reverse the anticoagulant effects of apixaban and rivaroxaban in patients with life-threatening bleeding. As the use of factor Xa inhibitors increases, understanding the role of andexanet alfa in urgent bleeding management has become critical. The activity covers dosing regimens, administration protocols, and important safety considerations, including thrombotic risks and the need for prompt re-initiation of anticoagulation. Special populations, drug interactions (notably with unfractionated heparin), and adverse effect profiles are addressed to support safe clinical decision-making. By engaging in this activity, clinicians enhance their competence in the multidisciplinary management of factor Xa inhibitor–associated bleeding and optimize patient outcomes through evidence-based use of andexanet alfa.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Mirembe Reed declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Diala Nicolas declares no relevant financial relationships with ineligible companies.

References

    1. Heo YA. Andexanet Alfa: First Global Approval. Drugs. 2018 Jul;78(10):1049-1055. - PMC - PubMed
    1. Jaspers T, Shudofsky K, Huisman MV, Meijer K, Khorsand N. A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor-related major bleeding. Res Pract Thromb Haemost. 2021 May;5(4):e12518. - PMC - PubMed
    1. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015 Dec 17;373(25):2413-24. - PubMed
    1. Writing Committee Members. Thompson A, Fleischmann KE, Smilowitz NR, de Las Fuentes L, Mukherjee D, Aggarwal NR, Ahmad FS, Allen RB, Altin SE, Auerbach A, Berger JS, Chow B, Dakik HA, Eisenstein EL, Gerhard-Herman M, Ghadimi K, Kachulis B, Leclerc J, Lee CS, Macaulay TE, Mates G, Merli GJ, Parwani P, Poole JE, Rich MW, Ruetzler K, Stain SC, Sweitzer B, Talbot AW, Vallabhajosyula S, Whittle J, Williams KA. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024 Nov 05;84(19):1869-1969. - PubMed
    1. Connolly SJ, Sharma M, Cohen AT, Demchuk AM, Członkowska A, Lindgren AG, Molina CA, Bereczki D, Toni D, Seiffge DJ, Tanne D, Sandset EC, Tsivgoulis G, Christensen H, Beyer-Westendorf J, Coutinho JM, Crowther M, Verhamme P, Amarenco P, Roine RO, Mikulik R, Lemmens R, Veltkamp R, Middeldorp S, Robinson TG, Milling TJ, Tedim-Cruz V, Lang W, Himmelmann A, Ladenvall P, Knutsson M, Ekholm E, Law A, Taylor A, Karyakina T, Xu L, Tsiplova K, Poli S, Kallmünzer B, Gumbinger C, Shoamanesh A, ANNEXA-I Investigators Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. N Engl J Med. 2024 May 16;390(19):1745-1755. - PubMed

Publication types

LinkOut - more resources